Mark Sita

Customer support | Investor

[Daily Stoic @dailystoic]

"The only constant is change." - Heraclitus

[Thomson Reuters HighQ @HighQ]

The problem isn't data access policies. It's compliance confidence. Thomson Reuters has partnered with Syncly to bring governance directly into HighQ workflows, so teams stay in control.

Find out more: https://t.co/Lha1j2wJMU

[Elon Musk @elonmusk]

𝕏 Money early public access will launch next month

[Botanix Pharmaceuticals Ltd @BotanixPharma]

#Botanix has entered into documentation with Kreos Capital for a loan facility of up to US$30 million (~A$48 million). The facility enhances our financial flexibility to support growth and strategic initiatives. Read the ASX Release: https://t.co/DDfD15gL3x
$BOT #ASX #dermatology

[Navalism @NavalismHQ]

"There is no failure, only feedback."

@naval

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT | #Botanix is pleased to share the latest Euroz Hartleys analyst report on Botanix, maintaining a price target of $0.80. Read the full report: https://t.co/2cmNexH9Qv $BOT #biotech #pharma #dermatology #sweat #invest

[Mark Sita @marksita5]

Here is a youtube video of the latest investor presentation by @BotanixPharma about Sofdra
https://t.co/T8Q7kokjIS

[Alex Sundich @AlexSundich]

S&P DJI has announces quarterly rebalancing of ASX indices effective 24 March. In a world 🌍 of passive investing and “index hugging”, whether your stocked is added to or (heaven forbid!) removed from an index is vital. Full list here👇. #ASX #Equities https://t.co/gFuQZsfexn

[Botanix Pharmaceuticals Ltd @BotanixPharma]

Check out the latest expert insights from @SGHiscockandCo ✨
https://t.co/BD4nmH2BD7

[Ian Cassel @iancassel]

New Article

The best stock ideas are hated or unknown in the beginning and loved in the end.

https://t.co/9HuMWIE783

[Botanix Pharmaceuticals Ltd @BotanixPharma]

🗞 Did you catch us in the @FinancialReview? An article featuring commentary from Lennox Capital’s Liam Donohue, profiles @BotanixPharma as an ASX favourite. See it here 👉 https://t.co/tKmr8hZv8s $BOT #ASX #pharma #innovation #dermatology #hyperhidrosis #FDA

[Intl Hyperhidrosis S @WeKnowSweat]

Thanks to @DermTimes for covering the latest in #hyperhidrosis treatment, confirming the safety & efficacy of Sofdra™! Access this groundbreaking treatment w an exclusive offer: https://t.co/h9qTvLnN7J

Read the full article here: https://t.co/R9P3jOaTpk
@BotanixPharma

[Shayan @shayan_]

Grok is now free for everyone on X! 🎉

Tap on the [ / ] icon in the bottom nav bar or head to https://t.co/jYWsGjr39I to give it a try!

[Botanix Pharmaceuticals Ltd @BotanixPharma]

Ascent Health, second largest Payer (insurer) organisation in the US, will now cover Sofdra™ (sofpironium) topical gel, 12.45%. Ascent represents approximately 65 million (nearly 40%) of US commercial lives. View release. https://t.co/K1h4e9Cs24 $BOT #dermatology #hyperhidrosis

[CMicrocaps @CMicrocaps]

$QHL the latest asx microcap to get a massive takeover bid.

Which stock is next?

[Mark Sita @marksita5]

Sofdra has some good reviews so far - the new treatment for excessive sweating from @BotanixPharma

https://t.co/RypvzwmQpl

[Naval @naval]

The best thing about @elonmusk is that he makes me question if I’m thinking big enough with my life.

[Intl Hyperhidrosis S @WeKnowSweat]

The Wait Is (Almost) Over! FDA OKs NEW, At-Home, Sweat-Less Treatment for Underarm #ExcessiveSweating > https://t.co/6Q9AYAdm3y
#KnowSweat #Hyperhidrosis #SweatyArmpits #HyperhidrosisInnovation

[bernsta @bernstaaaaa]

$BOT commercial day webinar presentation notes released. Insane opportunity. Working directly with telehealth provider upscript health and a direct line into the international hyperhidrosis society for Sofdra. FDA approved. Worth a read. Full insurance coverage for suffers. Circa $762 mill cap. Plenty of upside.

[Botanix Pharmaceuticals Ltd @BotanixPharma]

$BOT | Appendix 4E released 👉 https://t.co/3wBXEvxLkT. Mark your calendar for the Company’s Commercial Day Webinar on Tuesday 17 September 10:30am AEST / 8:30am AWST which will provide an update on commercial launch plans and market insights for Sofdra™. Registration to follow.